Extra-domain A containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody

Abstract Aims Pulmonary vascular and right ventricular (RV) remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analysed the functional role of the extra domain A-containing fibronectin (ED-A+ Fn) for the development of PH by comparing ED-A+ Fn knockout (KO) and wild-type (WT) mice as well as the effects of an antibody-based therapeutic approach in a model of monocrotaline (MCT) -induced PH, which will be validated in a model of Sugen 5416/hypoxia-induced PH. Methods and results PH was induced using MCT (PH mice). Sixty-nine mice were divided into the following groups: sham-treated controls (WT: n = 7; KO: n = 7), PH mice without specific treatment (WT: n = 12; KO: n = 10), PH mice treated with a dual endothelin receptor antagonist (macitentan; WT: n = 6; KO: n = 11), WT PH mice treated with the F8 antibody, specifically recognizing ED-A+ Fn, (n = 8), and WT PH mice treated with an antibody of irrelevant antigen specificity (KSF, n = 8). Compared to controls, WTPH mice showed a significant elevation of the RV systolic pressure (P = 0. 04) and RV functional impairment including increased basal RV (P = 0. 016) diameter or tricuspid annular plane systolic excursion (P = 0. 008). In contrast, KO PH did not show such effects compared to controls (P = n. s. ). In WTPH mice treated with F8, haemodynamic and echocardiographic parameters were significantly improved compared to untreated WTPH mice or those treated with the KSF antibody (P 0. 05). On the microscopic level, KOPH mice showed significantly less tissue damage compared to the WTPH mice (P = 0. 008). Furthermore, lung tissue damage could significantly be reduced after F8 treatment (P = 0. 04). Additionally, these findings could be verified in the Sugen 5416/hypoxia mouse model, in which F8 significantly improved echocardiographic, haemodynamic, and histologic parameters. Conclusion ED-A+ Fn is of crucial importance for PH pathogenesis representing a promising therapeutic target in PH. We here show a novel therapeutic approach using antibody-mediated functional blockade of ED-A+ Fn capable of attenuating and partially reversing PH-associated tissue remodelling.